Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celgene Corporation CELG

Healthcare Drug Manufacturers - Major
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma... see more

Recent & Breaking News (NDAQ:CELG)

CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG

GlobeNewswire May 18, 2018

Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

Benzinga.com  May 18, 2018

Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions

Business Wire May 16, 2018

Hagens Berman Reminds Investors in Celgene Corporation (CELG) of the May 29, 2018 Securities Class Action Lead Plaintiff Deadline

PR Newswire May 16, 2018

Nohla Therapeutics Announces Closing of $45 Million Series B Financing

GlobeNewswire May 15, 2018

Analyst: Trump's 'Naming And Shaming' Campaign To Build Pharma Headline Risk

Benzinga.com  May 15, 2018

Celgene Corporation to Webcast at Upcoming Investor Conferences and Events

Business Wire May 14, 2018

CELGENE SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG

GlobeNewswire May 11, 2018

Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Patterson Companies, Inc. Investors (PDCO)

Business Wire May 10, 2018

CLASS UPDATE: The Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)

Business Wire May 9, 2018

Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Benzinga.com  May 9, 2018

CELG EXPANDED CLASS: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018

Business Wire May 7, 2018

CELGENE SHAREHOLDER ALERT: ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit against Celgene Corporation - CELG

Business Wire May 4, 2018

Hagens Berman Alerts Investors in Celgene Corporation to the Expanded Class Period and Reminds Them of the May 29, 2018 Securities Class Action Lead Plaintiff Deadline

GlobeNewswire May 4, 2018

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Celgene Corporation of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018

Business Wire May 4, 2018

Celgene CEO: Strong Q1 Led To Improved Full-Year Guidance

Benzinga.com  May 4, 2018

Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down

Benzinga.com  May 4, 2018

Celgene Reports First Quarter 2018 Operating and Financial Results

Business Wire May 4, 2018

10 Stocks To Watch For May 4, 2018

Benzinga.com  May 4, 2018

Earnings Scheduled For May 4, 2018

Benzinga.com  May 4, 2018